Product Overview: Novomix 30 Flexpen Novo Nordisk
Novomix 30 FlexPen Novo Nordisk is a biphasic insulin aspart suspension that represents a significant advancement in diabetes research applications. This pharmaceutical-grade preparation combines rapid-acting insulin aspart with protaminated insulin aspart in a 30:70 ratio, providing researchers with a comprehensive tool for investigating glucose homeostasis mechanisms. The FlexPen delivery system offers precise dosing capabilities essential for controlled laboratory investigations. Research facilities examining Stroid UK Shop frequently utilise biphasic insulin formulations to study postprandial glucose responses and sustained glycaemic control mechanisms.
Laboratory Applications
This insulin preparation serves crucial roles in endocrinological research, particularly when investigating the dual-phase insulin response patterns observed in physiological conditions. The rapid-acting component enables researchers to examine immediate glucose uptake mechanisms, while the intermediate-acting fraction allows for extended metabolic pathway analysis. Studies evaluating insulin preparations and metabolic research compounds benefit from the predictable pharmacokinetic profile that Novomix 30 provides. Research applications include glucose clamp studies, insulin sensitivity assessments, and comparative analyses against other diabetes therapeutic approaches.
Product Specifications
| Parameter | Specification |
|---|---|
| Active Component | Biphasic insulin aspart 30:70 |
| Manufacturer | Novo Nordisk |
| Delivery System | FlexPen prefilled device |
| Concentration | 100 units/mL |
| Storage Requirements | 2-8°C refrigeration |
| Research Applications | Glucose metabolism studies |
Research facilities studying performance enhancement compounds often require baseline insulin preparations for comparative metabolic analyses, while investigations into peptide hormones and regulatory factors benefit from standardised insulin controls.
Research Compliance Statement
Novomix 30 FlexPen Novo Nordisk is supplied exclusively for in-vitro laboratory research purposes. This product is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must maintain appropriate laboratory conditions and follow institutional biosafety protocols when handling insulin preparations. All investigations should be conducted within approved research frameworks with proper documentation and safety measures.
